Sanders Calls for Reduced Prices on Ozempic, Citing New Study on Production Costs

Senator Bernie Sanders urges Novo Nordisk to lower Ozempic prices after a study reveals it costs less than $25 to produce, highlighting a significant markup.

A Yale University study finds that weight-loss and diabetes drugs like Ozempic and Wegovy can be produced for less than $25, but retail for over $1,000 monthly.
Sanders criticizes the high cost of Ozempic, comparing U.S. prices unfavorably with those in Canada and Germany, and warns of potential impacts on Medicare.
Novo Nordisk, the manufacturer, emphasizes efforts to make drugs more affordable and highlights significant investments in research and development.
Sanders plans to meet with Novo Nordisk's CEO to discuss lowering Ozempic's price, amidst concerns over affordability for Americans.
The Biden administration has negotiated prices for other drugs, but Medicare and Medicaid typically do not cover weight-loss drugs like Wegovy, limiting access.